DALLAS--(BUSINESS WIRE)--AllerVie Clinical Research, an affiliate of AllerVie Health and a nationally recognized network of clinical research sites, today announced the appointment of Dr. Weily Soong as its new chief research innovation officer. Formerly AllerVie’s chief medical officer, Soong will lead the company’s efforts to drive innovation through the advancement of new therapies and diagnostics for asthma, allergies and other related immunological conditions at AllerVie Clinical Research.
“I’m thrilled for the opportunity to work with such a strong team to continue advancing AllerVie’s Clinical Research division forward,” said Soong. “I am passionate about the impact clinical research has on patient care, and we are in a time of meaningful advancement in therapies, management, and treatment of allergic and immunologic diseases.”
The public demand is greater than ever for innovative healthcare, excellent customer service, and increased access to these services. In 2022 alone, AllerVie Health served over 100,000 patients across 12 states and more than 250,000 patient visits.
“In his new role, Dr. Soong’s deep understanding of allergy and asthma-related clinical research studies will be invaluable as we continue to grow our company and advance the clinical research field,” said Chris Roussos, CEO of AllerVie Health. “I consider his expertise a vital part of our team and an invaluable asset for our patients.”
In addition to this new role with AllerVie Clinical Research, Soong is currently a physician in AllerVie’s Birmingham practice, formerly known as Alabama Allergy and Asthma Center, where he has worked for nearly 17 years. He is also the section chief of allergy and immunology for the Birmingham Veterans Administration Medical Center. Soong completed his Internal Medicine residency at Yale University in New Haven, Connecticut, and remained at Yale for his Allergy and Clinical Immunology Fellowship training. He is also the author of numerous scientific-related pieces in the field of allergies and asthma, and his works have been featured in several publications, including the “National Library of Medicine,” the “Journal of the American Academy of Dermatology,” and the “Annals of Allergy, Asthma, & Immunology,” among others.
Headquartered in Dallas, AllerVie Health is a national network of board-certified allergists and immunologists partnering together for the advancement of patient care, serving patients across 12 states in 76 clinic locations.
About AllerVie Health
AllerVie provides world-class allergy and immunology services to millions of Americans impacted by allergies. Our providers are committed to establishing the allergy and immunology gold standard, expanding access to best-in-class care, and bringing relief and renewed vitality to the millions of Americans affected annually, many of whom live in underserved communities today. AllerVie is relentlessly dedicated to clinical excellence, creating an improved patient experience, and supporting the development of advanced allergy and immunology-focused therapeutics and treatment options. With AllerVie Health, our patients can feel their best, reclaim their lives, and live in freedom! To learn more, visit www.allervie.com.
About AllerVie Clinical Research
AllerVie Clinical Research, an affiliate of AllerVie Health, conducts clinical studies in adult and pediatric patients, contributing to the advancement of new therapies for asthma, allergies, and other related immunological conditions. We provide access to otherwise unavailable treatments to patients suffering from these conditions. As the fastest growing national network of clinical research sites specializing in allergy and asthma-related studies, AllerVie Clinical Research provides comprehensive care to patients nationwide employing the most efficacious and up-to-date treatments—including biologics. Highly regarded for their standards of excellence, our providers have been conducting clinical trials for pharmaceutical companies and Contract Research Organizations since 1998, giving us more than 20 years of successful clinical research experience in this area of immunological diseases. To learn more, visit www.allervieclinicalresearch.com.
